Cargando…
Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?
It is commonly assumed that neutralizing Mabs that bind to the HIV-1 Env glycoprotein are more specific reagents than anti-HIV-1 polyclonal antisera and that knowledge of the structure of these Mabs facilitates the rational design of effective HIV-1 vaccine immunogens. However, after more than ten y...
Autor principal: | Van Regenmortel, Marc H V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AIMS Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690275/ https://www.ncbi.nlm.nih.gov/pubmed/29546103 http://dx.doi.org/10.3934/publichealth.2015.2.183 |
Ejemplares similares
-
Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021) -
Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015) -
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015) -
Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021) -
Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)